• G L Ceresoli, P A Zucali, M Mencoboni, M Botta, F Grossi, D Cortinovis, N Zilembo, C Ripa, M Tiseo, A G Favaretto, H Soto-Parra, F De Vincenzo, A Bruzzone, E Lorenzi, L Gianoncelli, B Ercoli, L Giordano, and A Santoro.
• Department of Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy. giovanni_luca.ceresoli@gavazzeni.it
• Br. J. Cancer. 2013 Aug 6;109(3):552-8.

BackgroundThe aim of this open label phase II study (NCT00407459) was to assess the activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined with pemetrexed and carboplatin in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM).MethodsEligible patients received pemetrexed 500 mg m(-2), carboplatin area under the plasma concentration-time curve (AUC) 5 mg ml(-1) per minute and bevacizumab 15 mg kg(-1), administered intravenously every 21 days for six cycles, followed by maintenance bevacizumab. The primary end point of the study was progression-free survival (PFS). A 50% improvement in median PFS in comparison with standard pemetrexed/platinum combinations (from 6 to 9 months) was postulated.ResultsSeventy-six patients were evaluable for analysis. A partial response was achieved in 26 cases (34.2%, 95% CI 23.7-46.0%). Forty-four (57.9%, 95% CI 46.0-69.1%) had stable disease. Median PFS and overall survival were 6.9 and 15.3 months, respectively. Haematological and non-haematological toxicities were generally mild; however, some severe adverse events were reported, including grade 3-4 fatigue in 8% and bowel perforation in 4% of patients. Three toxic deaths occurred.ConclusionThe primary end point of the trial was not reached. However, due to the limitation of a non-randomised phase II design, further data are needed before drawing any definite conclusion on the role of bevacizumab in MPM.

34 keywords...

hide…